All Posts Tagged With: "FRX"
(TEVA) Teva Pharmaceutical Industries Active on the Generics Front
Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic...
(FRX) Forest Laboratories and Janssen Pharmaceutica Sue Generic Players
Forest Laboratories, Inc. (FRX) and Janssen Pharmaceutica NV, a Johnson & Johnson (JNJ) company, recently filed a joint lawsuit against...
(FRX) Forest Laboratories Earns Positive News on Pipeline
Forest Laboratories, Inc. (FRX) recently reported back-to-back positive news on the pipeline front. The company and partner Gedeon Richter Plc. announced that their late-stage anti-psychotic candidate, cariprazine,...
(FRX) Forest Laboratories Learns of Positive Results on Gedeon Drug
Forest Laboratories, Inc. (FRX) and partner Gedeon Richter recently presented positive top-line results on their antipsychotic candidate, cariprazine (RGH-188). Preliminary top-line results were presented...
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a...
(TEVA) Teva Pharmaceutical Industries Provides In-Line 2012 Outlook
Teva Pharmaceutical Industries Ltd. (TEVA) recently provided guidance for 2012. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. Guidance was generally in line...
(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well.
Until recently, most commercialization efforts were focused on the U.S....
(AAPL) A Busy Week Ahead – Earnings Preview
Earnings Preview 10/14/11
While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&P 500.
Thus, by the end of the week we...
(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
(AAPL) 2011 Second Quarter Earnings Preview – Detailed
Earnings Preview 7/15/11
Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are...
(FRX) Forest Laboratories Announces Viibryd Launch
Forest Laboratories, Inc. (FRX) recently announced the launch of Viibryd (vilazodone HCl) tablets in the US. Viibryd, which is approved for the treatment of adults with major depressive disorder, is available...
(FRX) Forest Laboratories Seeks FDA Nod for COPD Drug
Forest Laboratories, Inc. (FRX) and partner Almirall, S.A. recently announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for their chronic obstructive pulmonary...
(PFE) Pfizer’s Lyrica Holds Promise
Pfizer Inc. (PFE) recently presented positive top-line data on its blockbuster drug, Lyrica. Pfizer said that Lyrica met the primary endpoint in a study that was being conducted in patients with chronic central...
(THRX) Theravance Analyst Maintains Neutral on Shares
We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results.
Theravance’s first...
(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
(THRX) Theravance Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results.
Theravance’s first...
(FRX) Forest Labs Fourth Quarter 2011 Earnings Preview
Forest Labs (FRX) is all set to announce its fourth quarter and fiscal 2011 results on April 19. The Zacks Consensus Estimate for the fourth quarter is $1.07, representing a year-over-year...
(THRX) Theravance Analyst Maintains Neutral on Shares
We are maintaining our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $25.00 after the company’s fourth quarter and fiscal year 2010 financial results.
Theravance’s...
(AMAT) Stock Market News for February 23, 2011 – Market News
The fear gauge Volatility Index (VIX) surged to its highest level since May last year and benchmark indices suffered sharp declines on Tuesday. Unrest in the Middle East and North Africa continued as immediately after the overthrow of leaders in Egypt and Tunisia, demonstrators...
(BHP) Company News for February 23, 2011 – Corporate Summary
• Wal-Mart (NYSE:WMT) reported Q4 EPS of $1.34, ahead of the Zacks Consensus Estimate of $1.31 per share
• Petrohawk Energy Corp. (NYSE:HK) reported Q4 EPS of...
(CYPB) Cypress Bioscience Reports Wider Loss
Cypress Bioscience, Inc. (CYPB) reported a net loss of 94 cents per share in the third quarter, significantly higher than the Zacks Consensus Estimate of a loss of 33 cents and the year ago loss of 12 cents....
(SHPGY) Shire Beats Earnings Expectations – Increases Earnings Outlook
Shire plc (SHPGY) posted earnings of $1.16 per American Depositary Share (ADS) during the third quarter of 2010, beating the Zacks Consensus Estimate of 98 cents and the year-ago earnings of 49 cents per...
(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
(AZO) Company News for September 21, 2010
• Nokia (NYSE:NOK) for the second time announced delivery delays of its N8 model smartphone
• ConAgra (NYSE:CAG) announced worse-than-expected fiscal first quarter earnings of 34 cents a share, off estimates of 39 cents, on revenues of $2.82 billion, below estimates...
(FRX) Forest Laboratories Responds to US Food and Drug Administration Letter
Forest Laboratories Inc. (FRX) recently announced that it has submitted a response to the complete response letter (CRL) issued by the US Food and Drug Administration (FDA) in mid-May for...
(JAZZ) Jazz Pharmaceuticals JZP-6 Faces US Food and Drug Administration Setback
Jazz Pharmaceuticals Inc. (JAZZ) recently announced that the US Food and Drug Administration’s (FDA) joint advisory committee voted against the approval of the company’s fibromyalgia treatment, JZP-6....
(MRK) Pharma Merger Mania is Heating Up
by Marc Lichtenfeld, Healthcare Expert
Wednesday, July 28, 2010: Issue #1311
In...
(MRK) Big Pharma Has a Big Problem and Merger Mania is Heating Up
by Marc Lichtenfeld, Healthcare Expert
Wednesday, July 28, 2010: Issue #1311
In...
(FRX) Forest Laboratories Settles Patent Fight
Forest Laboratories Inc. (FRX) and partner Merz GmbH & Co. KGaA recently entered into a patent litigation settlement agreement with about 10 companies that were seeking to launch their...
(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect...